Cantabio Pharmaceuticals Inc. (CTBO) 0.7500 $CTBO
Post# of 273254
Posted On: 09/22/2016 3:09:40 AM
Cantabio Pharmaceuticals Inc. (CTBO) 0.7500 $CTBO
Cantabio Pharmaceuticals to Present at 2016 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai
GlobeNewswire - Mon Sep 19, 8:00AM CDT
Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's (PD) and other related neurodegenerative diseases, today announced that members of its senior management team will participate and present in the 2016 Silicon Valley Bank Healthcare Capital and Connections Summit on September 22, 2016 at 4pm in Shanghai, China at the Grand Hyatt Shanghai, Jin Mao Tower.
Cantabio Pharmaceuticals licenses Tau protein targeting therapeutic program from University of Cambridge for the potential treatment of Alzheimer's Disease and related Dementias
GlobeNewswire - Wed Sep 07, 9:19AM CDT
Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced the completion of a licensing agreement with Cambridge Enterprise that gives the company access to intellectual property from research targeting the Tau protein for the treatment of "Tauopathies" such as Alzheimer's disease (AD) and Dementia. The aggregation of Tau is a hallmark of Tauopathies and is strongly linked to the onset and progression of these diseases. The licensed therapeutic program contains data and know-how for a set of novel, small molecule drug candidates that bind to the Tau protein and reduce its misfolding and aggregation.
Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company's Therapeutic Candidates Targeting DJ-1 Protein to Treat Parkinson's Disease
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced its collaboration with the Neuroscience Research Group at the University of Antioquia in Colombia, to further evaluate the company's DJ-1 protein-targeting small molecule pharmaceutical chaperone drug candidates in development for the treatment of Parkinson's disease (PD). The partnership brings together Cantabio's novel approach and the University of Antioquia's research excellence on the role of oxidative stress in PD and other neurodegenerative diseases.
Cantabio Pharmaceuticals Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with NovAliX
GlobeNewswire - Tue Apr 12, 11:00AM CDT
Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) announced today a new preclinical therapeutic program for Alzheimer's Disease which it is pursuing through its drug discovery partnership with NovAliX. This program is aimed at the development of small molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a key element in the onset and progression of Alzheimer's disease.
CANTABio and Gardedam Therapeutics complete Merger to Tackle Development of Novel Therapeutics for Alzheimer's and Parkinson's Disease
GlobeNewswire - Mon Dec 21, 12:00PM CST
Cantabio Pharmaceuticals, Inc. ("Cantabio"
(OTCQB:CTBO) is pleased to announce the completion of its reverse merger (the "Merger" with Gardedam Therapeutics, Inc. ("Gardedam". The effective date of the Merger is December 18th, 2015.
Cantabio Pharmaceuticals to Present at 2016 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai
GlobeNewswire - Mon Sep 19, 8:00AM CDT
Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's (PD) and other related neurodegenerative diseases, today announced that members of its senior management team will participate and present in the 2016 Silicon Valley Bank Healthcare Capital and Connections Summit on September 22, 2016 at 4pm in Shanghai, China at the Grand Hyatt Shanghai, Jin Mao Tower.
Cantabio Pharmaceuticals licenses Tau protein targeting therapeutic program from University of Cambridge for the potential treatment of Alzheimer's Disease and related Dementias
GlobeNewswire - Wed Sep 07, 9:19AM CDT
Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced the completion of a licensing agreement with Cambridge Enterprise that gives the company access to intellectual property from research targeting the Tau protein for the treatment of "Tauopathies" such as Alzheimer's disease (AD) and Dementia. The aggregation of Tau is a hallmark of Tauopathies and is strongly linked to the onset and progression of these diseases. The licensed therapeutic program contains data and know-how for a set of novel, small molecule drug candidates that bind to the Tau protein and reduce its misfolding and aggregation.
Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company's Therapeutic Candidates Targeting DJ-1 Protein to Treat Parkinson's Disease
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced its collaboration with the Neuroscience Research Group at the University of Antioquia in Colombia, to further evaluate the company's DJ-1 protein-targeting small molecule pharmaceutical chaperone drug candidates in development for the treatment of Parkinson's disease (PD). The partnership brings together Cantabio's novel approach and the University of Antioquia's research excellence on the role of oxidative stress in PD and other neurodegenerative diseases.
Cantabio Pharmaceuticals Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with NovAliX
GlobeNewswire - Tue Apr 12, 11:00AM CDT
Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) announced today a new preclinical therapeutic program for Alzheimer's Disease which it is pursuing through its drug discovery partnership with NovAliX. This program is aimed at the development of small molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a key element in the onset and progression of Alzheimer's disease.
CANTABio and Gardedam Therapeutics complete Merger to Tackle Development of Novel Therapeutics for Alzheimer's and Parkinson's Disease
GlobeNewswire - Mon Dec 21, 12:00PM CST
Cantabio Pharmaceuticals, Inc. ("Cantabio"
(OTCQB:CTBO) is pleased to announce the completion of its reverse merger (the "Merger" with Gardedam Therapeutics, Inc. ("Gardedam". The effective date of the Merger is December 18th, 2015. 
(0)
(0)Scroll down for more posts ▼